ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2,2,Bone marrow necrosis,Haematological disorders,Haematological disorders NEC,Blood,N
3,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
3,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
3,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
3,4,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
4,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
4,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
5,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
6,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
7,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
7,2,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,Y
7,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
8,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
8,2,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,Y
8,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
9,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
9,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
9,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
9,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
10,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
10,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
10,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
10,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
10,5,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
10,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
11,1,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
12,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
13,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
13,2,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
13,3,Headache,Headaches NEC,Headaches,Nerv,N
14,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
14,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
14,3,Headache,Headaches NEC,Headaches,Nerv,N
14,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
14,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
15,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
15,2,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
15,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
16,1,Nephropathy toxic,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
17,1,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
18,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
18,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
19,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
20,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
20,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
20,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
21,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
21,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
22,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
23,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
23,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
23,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
23,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
24,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
25,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
26,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
27,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
28,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
29,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
30,1,Chondritis,Cartilage disorders,"Tendon, ligament and cartilage disorders",Musc,N
31,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
31,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
32,1,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
33,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
34,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
35,1,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
36,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
36,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
37,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
38,1,Coombs negative haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
39,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
39,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
39,3,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
39,4,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
39,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
40,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
41,1,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
41,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
42,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
42,2,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
43,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
44,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
45,1,Injection site necrosis,Injection site reactions,Administration site reactions,Genrl,N
45,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
45,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
46,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
47,1,Blood creatine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
47,2,Blood creatinine decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
48,1,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
49,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
49,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
49,3,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
49,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
49,5,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
49,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
49,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
50,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
51,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
51,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
52,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
53,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
54,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
54,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
54,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
55,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
55,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
55,3,Myelodysplastic syndrome transformation,Myelodysplastic syndromes,Leukaemias,Neopl,N
55,4,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
56,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
56,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
57,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
58,1,Injection site necrosis,Injection site reactions,Administration site reactions,Genrl,N
59,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
60,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
61,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
61,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
62,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
62,2,Orbital apex syndrome,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,Y
62,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
63,1,Carotid artery stenosis,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
63,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
64,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
64,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
64,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
64,4,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
65,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
65,2,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
66,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
66,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
67,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
68,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
69,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
69,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
69,3,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
69,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
70,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
71,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
72,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
73,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
74,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
74,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
74,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
75,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
75,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
75,3,Infarction,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
76,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
76,2,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
77,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
77,2,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
78,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
78,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
79,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
79,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
79,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
79,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
80,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
80,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
80,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
81,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
82,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
82,2,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
83,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
83,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
83,3,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
83,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
83,5,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
83,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
84,1,Splenic rupture,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
85,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
85,2,Headache,Headaches NEC,Headaches,Nerv,N
85,3,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
86,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
86,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
86,3,Myelodysplastic syndrome transformation,Myelodysplastic syndromes,Leukaemias,Neopl,N
86,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
87,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
87,2,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
87,3,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,Y
88,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
88,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
88,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
89,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
90,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
90,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
91,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
92,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
92,2,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
93,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
94,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
95,1,Disseminated intravascular coagulation,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
95,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
95,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
96,1,Ankle fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
96,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
96,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
97,1,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
97,2,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
98,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
98,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
98,3,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
99,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
99,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
100,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
100,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
101,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
102,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
102,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
103,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
103,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
104,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
105,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
105,2,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
105,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
106,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
106,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
107,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
107,2,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
107,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
108,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
108,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
108,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
109,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
110,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
110,2,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
110,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
110,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
111,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
111,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
112,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
112,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
112,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
113,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
114,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
114,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
115,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
116,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
117,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
118,1,Injection site haematoma,Injection site reactions,Administration site reactions,Genrl,N
119,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
119,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
119,3,Injection site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
119,4,Pyoderma gangrenosum,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
119,5,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
119,6,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
119,7,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
119,8,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
120,1,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,Y
121,1,Injection site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
121,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
121,3,Injection site necrosis,Injection site reactions,Administration site reactions,Genrl,N
122,1,Eyelid oedema,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
122,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
122,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
123,1,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
123,2,Injection site haematoma,Injection site reactions,Administration site reactions,Genrl,N
123,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
124,1,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
125,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
125,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
125,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
126,1,Blast cell proliferation,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,Y
127,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
127,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
128,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
129,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
130,1,Coma hepatic,Coma states,Neurological disorders NEC,Nerv,Y
130,2,Hepatic encephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
130,3,Hyperbilirubinaemia,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
130,4,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
131,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
131,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
132,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
133,1,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
134,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
134,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
134,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
135,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
135,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
135,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
136,1,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
136,2,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
136,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
136,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
136,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
136,6,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
136,7,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
136,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
136,9,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
137,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
138,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
139,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
140,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
141,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
142,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
143,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
143,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
144,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
145,1,Osteonecrosis of jaw,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
146,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
146,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
147,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
148,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
148,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
149,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
150,1,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
151,1,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
152,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
153,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
154,1,Chloroma,Leukaemias myeloid NEC,Leukaemias,Neopl,N
155,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
156,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
156,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
157,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
158,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
158,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
159,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
159,2,Areflexia,Abnormal reflexes,Neurological disorders NEC,Nerv,N
159,3,Dizziness postural,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
160,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
161,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
162,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
162,2,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
162,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
162,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
162,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
162,6,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
163,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
163,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
163,3,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
163,4,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
163,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
163,6,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
163,7,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
163,8,Purulent discharge,Infections NEC,Infections - pathogen unspecified,Infec,N
163,9,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
163,10,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
164,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
164,2,Fibrosis,Fibrosis NEC,Tissue disorders NEC,Genrl,N
165,1,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
166,1,Headache,Headaches NEC,Headaches,Nerv,N
167,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
168,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
168,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
168,3,Peripheral motor neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
169,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
169,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
170,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
171,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
171,2,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
172,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
172,2,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
172,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
172,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
172,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
173,1,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
173,2,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,N
173,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
173,4,Proctalgia,Anal and rectal pains,Anal and rectal conditions NEC,Gastr,N
173,5,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
174,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
174,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
175,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
176,1,Acute respiratory distress syndrome,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
176,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
176,3,Osteomyelitis,Bone and joint infections,Infections - pathogen unspecified,Infec,N
176,4,Respiratory tract infection,Infections NEC,Infections - pathogen unspecified,Infec,N
177,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
178,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
179,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
180,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
181,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
181,2,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
182,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
182,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
183,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
184,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
184,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
184,3,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
185,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
186,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
186,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
187,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
188,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
189,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
190,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
190,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
191,1,Motor neurone disease,Motor neurone diseases,Neuromuscular disorders,Nerv,N
192,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
192,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
193,1,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
193,2,Organising pneumonia,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
194,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
194,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
194,3,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
194,4,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
194,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
195,1,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
196,1,Acute left ventricular failure,Left ventricular failures,Heart failures,Card,N
196,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
197,1,Foetal exposure timing unspecified,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
197,2,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
197,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
198,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
199,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
199,2,Jaundice neonatal,Neonatal hepatobiliary disorders,Neonatal and perinatal conditions,Preg,N
199,3,Neonatal respiratory distress,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
199,4,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
200,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,Y
201,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
201,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
202,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
202,2,Transplant failure,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,N
203,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
204,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
205,1,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
206,1,Lung opacity,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
207,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
207,2,Device related sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
207,3,Graft versus host disease in liver,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
208,1,Anal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
209,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
210,1,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
211,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
212,1,Body temperature,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
212,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
212,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
213,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
213,2,Soft tissue necrosis,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
214,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
215,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
215,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
215,3,Synovitis,Synovial disorders,Synovial and bursal disorders,Musc,N
216,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
216,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
216,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
217,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
217,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
218,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
218,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
219,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
220,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
220,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
220,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
220,4,Enterococcal infection,Enterococcal infections,Bacterial infectious disorders,Infec,N
220,5,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
220,6,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
220,7,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
220,8,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
220,9,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
220,10,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
220,11,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
220,12,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
220,13,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
220,14,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
220,15,Skin laceration,Skin injuries NEC,Injuries NEC,Inj&P,N
220,16,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
221,1,Infection susceptibility increased,Infections NEC,Infections - pathogen unspecified,Infec,N
221,2,Pneumonia klebsiella,Klebsiella infections,Bacterial infectious disorders,Infec,Y
222,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
222,2,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
222,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
222,4,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
223,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
223,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
224,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
224,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
225,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
225,2,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
226,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
226,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
227,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
227,2,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
227,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
228,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
228,2,Foetal exposure timing unspecified,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
228,3,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
228,4,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
229,1,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
229,2,Transformation to acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
230,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
231,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
231,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
231,3,Injection site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
232,1,Pyoderma gangrenosum,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
233,1,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
233,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
234,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
234,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
234,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
234,4,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
235,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
236,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
236,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
236,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
236,4,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
237,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
238,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
239,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
239,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
239,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
240,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
240,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
240,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
240,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
241,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
241,2,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
241,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
242,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
242,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
243,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
244,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
245,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
245,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
246,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
246,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
247,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
247,2,Therapeutic response changed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
248,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
249,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
250,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,Y
251,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
251,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
252,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
252,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
253,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
253,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
253,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
253,4,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
254,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
254,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
254,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
255,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
255,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
256,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
256,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
257,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
257,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
258,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
258,2,Chondrocalcinosis,Crystal arthropathic disorders,Joint disorders,Musc,N
258,3,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
258,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
259,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
259,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
260,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
261,1,Angioimmunoblastic T-cell lymphoma refractory,Angioimmunoblastic T-cell lymphomas,Lymphomas non-Hodgkin's T-cell,Neopl,N
261,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
262,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
262,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
263,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
264,1,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
264,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
264,3,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
265,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
265,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
266,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
266,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
266,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
266,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
267,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
268,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
268,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
268,3,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
269,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
269,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
270,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
271,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
272,1,Nephropathy toxic,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
273,1,Catheter site haemorrhage,Implant and catheter site reactions,Administration site reactions,Genrl,N
273,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
273,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
273,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
273,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
274,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
275,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
276,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
276,2,Oral blood blister,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
276,3,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
277,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
277,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
278,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
278,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
278,3,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
279,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
279,2,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
280,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
281,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
281,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
281,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
281,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
282,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
282,2,Ocular hyperaemia,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
283,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
283,2,Headache,Headaches NEC,Headaches,Nerv,N
284,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
285,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
285,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
286,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
286,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
286,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
287,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
288,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
289,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
290,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
290,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
291,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
292,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
292,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
293,1,Blood bicarbonate decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
293,2,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
293,3,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
293,4,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
293,5,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
293,6,Electrolyte imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
293,7,Eosinophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,8,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,9,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,10,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,11,Mean cell haemoglobin concentration decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,12,Mean cell volume increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,13,Monocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,14,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,15,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
293,16,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
293,17,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,18,Red cell distribution width increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
293,19,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
293,20,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
293,21,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
294,1,Administration site rash,Administration site reactions NEC,Administration site reactions,Genrl,N
295,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
295,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
296,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
296,2,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
297,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
297,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
298,1,Hypogammaglobulinaemia,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
298,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
298,3,Lymphopenia,Leukopenias NEC,White blood cell disorders,Blood,N
298,4,Pneumocystis jirovecii infection,Pneumocystis infections,Fungal infectious disorders,Infec,N
298,5,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
298,6,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
298,7,Steroid diabetes,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
298,8,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
298,9,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
299,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
299,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
299,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
300,1,Hypogammaglobulinaemia,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
300,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
300,3,Lymphopenia,Leukopenias NEC,White blood cell disorders,Blood,N
300,4,Pneumocystis jirovecii infection,Pneumocystis infections,Fungal infectious disorders,Infec,N
300,5,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
300,6,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
300,7,Steroid diabetes,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
300,8,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
300,9,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
301,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
301,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
302,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
302,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
302,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
302,4,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
302,5,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
302,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
302,7,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
302,8,Neutrophil count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
302,9,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
302,10,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
302,11,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
303,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
303,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
303,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
303,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
304,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
304,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
304,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
304,4,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
305,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
305,2,Minimal residual disease,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
305,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
306,1,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
307,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
307,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
307,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
308,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
309,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
309,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
310,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
311,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
311,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
311,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
312,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
312,2,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,Y
313,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
313,2,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
314,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
314,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
314,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
315,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
315,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
316,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
317,1,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
318,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
318,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
319,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
319,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
319,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
319,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
319,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
320,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
320,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
320,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
320,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
321,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
321,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
322,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
323,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
323,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
323,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
324,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
325,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
326,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
327,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
328,1,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
329,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
330,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
330,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
331,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
332,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
333,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
334,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
335,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
336,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
336,2,Blood uric acid abnormal,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
336,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
336,4,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
337,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
338,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
338,2,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
338,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
338,4,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
338,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
338,6,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
338,7,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
338,8,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
338,9,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
338,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
338,11,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
338,12,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
338,13,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
338,14,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
338,15,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
338,16,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
339,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
339,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
340,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
341,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
342,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
343,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
343,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
343,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
344,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
344,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
345,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
345,2,Cardiomegaly,Myocardial disorders NEC,Myocardial disorders,Card,N
345,3,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
345,4,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
346,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
347,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
348,1,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
348,2,Pulmonary cavitation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
348,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
349,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
349,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
350,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
351,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
352,1,Bone marrow disorder,Haematological disorders,Haematological disorders NEC,Blood,N
353,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
354,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
354,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
355,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
356,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
357,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,Y
357,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
358,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
359,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
359,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
359,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
360,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
360,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
361,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
362,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
363,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
364,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
365,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
365,2,Peritoneal dialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
365,3,Post procedural sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
365,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
366,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
367,1,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
368,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
369,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
369,2,Cytomegalovirus colitis,Cytomegaloviral infections,Viral infectious disorders,Infec,N
369,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
369,4,Diarrhoea haemorrhagic,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
369,5,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
369,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
370,1,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
371,1,Cytomegalovirus colitis,Cytomegaloviral infections,Viral infectious disorders,Infec,N
371,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
372,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
372,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
373,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
373,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
373,3,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
374,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
375,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
376,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
377,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
377,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
377,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
378,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
379,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
380,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
380,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
381,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
381,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
381,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
382,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
382,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
383,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
384,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
385,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
386,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
387,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
388,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
389,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
389,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
389,3,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
389,4,Klebsiella bacteraemia,Klebsiella infections,Bacterial infectious disorders,Infec,Y
389,5,Large intestine perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
390,1,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
390,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
390,3,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
391,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
392,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
393,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
394,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
394,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
395,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
395,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
396,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
397,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
398,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
398,2,Minimal residual disease,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
398,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
399,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
399,2,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
399,3,Faecal calprotectin increased,Faecal analyses NEC,Gastrointestinal investigations,Inv,N
399,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
399,5,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
399,6,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
400,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
400,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
401,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
401,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
402,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
403,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
403,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
404,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
405,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
405,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
406,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
407,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
407,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
407,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
408,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
409,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
410,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
410,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
411,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
412,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
412,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
413,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,Y
414,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
415,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
416,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
416,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
416,3,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
416,4,Injection site papule,Injection site reactions,Administration site reactions,Genrl,N
417,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
417,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
418,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
419,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
420,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
420,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
421,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
421,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
422,1,Gouty tophus,Crystal arthropathic disorders,Joint disorders,Musc,N
422,2,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
423,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
424,1,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
424,2,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
425,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
425,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
425,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
426,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
426,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
427,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
427,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
428,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
429,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
429,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
430,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
430,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
431,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
432,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
433,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
434,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
435,1,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
436,1,Anal fistula,Gastrointestinal fistulae,Gastrointestinal conditions NEC,Gastr,N
437,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
437,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
438,1,Monocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
438,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
438,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
439,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
439,2,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
440,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
440,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
441,1,Cushingoid,Adrenal cortical hyperfunctions,Adrenal gland disorders,Endo,N
442,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
443,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
444,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
444,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
444,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
444,4,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
444,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
445,1,Cushingoid,Adrenal cortical hyperfunctions,Adrenal gland disorders,Endo,N
446,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
446,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
446,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
447,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
447,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
448,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
449,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
450,1,Aortic disorder,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
450,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
450,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
450,4,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
450,5,Venous aneurysm,Aneurysms and dissections non-site specific,Aneurysms and artery dissections,Vasc,N
451,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
452,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
453,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
453,2,Karyotype analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
454,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
454,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
455,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
456,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
456,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
456,3,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
457,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
458,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
458,2,Torsade de pointes,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
459,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
460,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
461,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
461,2,Abdominal rigidity,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
461,3,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
461,4,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
461,5,Amylase increased,Digestive enzymes,Gastrointestinal investigations,Inv,N
461,6,Aortic aneurysm,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,N
461,7,Gastric dilatation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
461,8,Gastric volvulus,Gastric and pyloric stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
461,9,Hepatic cyst,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
461,10,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
461,11,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
461,12,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
461,13,Pancreatitis relapsing,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
461,14,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
462,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,Y
462,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
463,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
463,2,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
463,3,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
463,4,Platelet transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
463,5,Red blood cell transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
464,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
464,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
465,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
465,2,Injection site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
466,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
466,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
466,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
466,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
467,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
467,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
467,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
467,4,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
468,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
468,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
468,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
469,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
469,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
470,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
471,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
471,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
472,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
472,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
473,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
473,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
473,3,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
474,1,Administration site rash,Administration site reactions NEC,Administration site reactions,Genrl,N
474,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
475,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
476,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
477,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
478,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
478,2,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
478,3,Prescription drug used without a prescription,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
479,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
479,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
480,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
480,2,Diastolic dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
480,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
480,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
481,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
481,2,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
481,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
